Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality

Aline N. Zouk, J. Michael Wells
European Respiratory Journal 2017 49: 1700750; DOI: 10.1183/13993003.00750-2017
Aline N. Zouk
1Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA
2UAB Lung Health Center, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Wells
1Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA
2UAB Lung Health Center, Birmingham, AL, USA
3Birmingham VA Medical Center, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jmwells@uabmc.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In a general population, the PA:A is associated with increased mortality in moderate to severe COPD http://ow.ly/L9S130bNuq7

For quite some time, we have known that pulmonary hypertension (PH) is associated with an increased risk of death in chronic obstructive pulmonary disease (COPD) [1, 2]. The occurrence of PH in the context of chronic lung diseases is often the result of hypoxic pulmonary hypertension and is classified as Group III PH by the World Health Organization (WHO) [3]. The diagnosis of PH requires a high index of suspicion, as symptoms are often vague and nonspecific, particularly among individuals with pre-existing respiratory disease. PH is defined by hemodynamic measurement during right-sided heart catheterisation (RHC), even though RHC is not routinely performed in COPD, because of the invasive nature of the procedure and the lack of efficacious treatments [4–6]. Comorbid PH independently accounts for worsening dyspnoea, fatigue, impaired exercise tolerance and poor quality of life in COPD [7, 8], and is associated with increased risk of hospitalisation and higher mortality [2, 3, 9].

With advances in imaging technologies, many studies have evaluated the utility of various noninvasive surrogate markers for PH. These include echocardiography [10, 11], cardiac magnetic resonance imaging (MRI) [12] and computed tomography (CT) [9, 13–17]. Recently, there has been significant interest in the use of CT in COPD, with several studies evaluating the utility of the ratio of the pulmonary artery to ascending aortic diameter (PA:A ratio) and pulmonary arterial enlargement [15–19]. The PA:A has been calculated in several cohorts of healthy patients and those with different chronic respiratory conditions, and correlates with PA pressures as measured by RHC [9, 15–17, 20–22] and worsening clinical outcomes [15, 17, 18, 20, 21, 23–25]. In a cohort of very severe COPD patients, the PA:A correlated with invasive haemodynamics, and a PA:A >1 independently predicted PH defined as a mean PA pressure >25 mmHg at right heart catheterisation with a sensitivity of 73% and a specificity of 84% [16]. Moreover, its presence was independently associated with an increased risk of severe COPD exacerbations [17] and an increased risk of cardiac injury and in-hospital mortality in individuals hospitalised with COPD exacerbations [18]. The PA:A ratio also predicts increased mortality in patients with advanced lung disease; a PA:A>1 was significantly associated with an increased risk of mortality in patients with very severe COPD who were undergoing evaluation for lung transplantation [15]. Similar findings were reiterated in a similar study on idiopathic pulmonary fibrosis (IPF) [20]. The associations between the PA:A and clinical outcomes in COPD and other diseases are shown in table 1. These studies however, have all been conducted in well-defined research populations or highly selected subgroups. Thus, little is known about the utility of the PA:A in a general population.

View this table:
  • View inline
  • View popup
TABLE 1

Associations between the ratio of the pulmonary artery to ascending aortic diameter (PA:A ratio) and clinical outcomes

In the current issue of The European Respiratory Journal, Terzikhan et al. [26] explored the association of the PA:A ratio and all-cause mortality in a Dutch general population. This study was conducted using the well-described Rotterdam cohort, a large prospective population-based cohort. It included 2197 participants, of which 222 (10.1%) had COPD. Participants were followed for a median of 8.8 years, with 423 (19.3%) deaths being reported. The mortality rate in the COPD subgroup was two-fold higher than that in the entire population, with cardiovascular events accounting for most of these deaths. The PA diameter in the general population was 26±3.7 mm, whereas the PA:A was 0.71±0.10. These findings are consistent with those from the Framingham Heart Study, in which a PA diameter of 29 mm was observed in men and 27 mm in women, and a PA:A ratio of 0.9 was established as normal [19]. The COPD cohort had a mean PA:A of 0.72±0.10, similar to the general population. PA enlargement defined as a PA:A>1 was only present in 17 subjects (0.77%); thus, the authors evaluated the PA:A as a continuous measure. The authors found an association between an elevated PA:A and increased risk of mortality in patients with COPD, but not in the general population. This association was primarily driven by findings in severe COPD. Moreover, in patients with moderate to severe COPD, there was a significantly increased risk of mortality at higher quartiles of the PA:A values, with those at the highest PA:A quartile exhibiting a three-fold risk of mortality compared to those in the lowest quartile. Furthermore, Terzikhan et al. found a significant association between the PA:A and PH, defined as a pulmonary artery systolic pressure (PASP) >40 mmHg on echocardiography in both non-COPD and COPD groups.

The increased risk of all-cause mortality observed in individuals with PA enlargement and COPD does not come as much of a surprise. Epidemiological studies focused on idiopathic pulmonary arterial hypertension have reported a low prevalence of the disease in the general population, estimated to be around 5.9 cases per million adults [27]. Therefore, the prevalence of PA abnormalities is also expected to be low. In contrast, the prevalence of PH in COPD is thought to be anywhere between 10%–85%, depending on the severity of the disease and the methods used for its diagnosis [16]. In addition, 20%–37% of patients with COPD have PA abnormalities, with a PA:A >1 [9, 16]. PH occurs more commonly in severe COPD and the development of elevated pulmonary artery pressures is often associated with hypoxia-mediated vascular changes [28]. Although the study by Terzikhan et al. confirmed the associations between the PA:A and metrics suggestive of PH on echocardiography, it is noteworthy that the PA:A ratio and PA enlargement are not absolutely indicative of PH. Mechanisms other than PH, including inflammation, airway remodelling [29] and hyperinflation also contribute to PA:A abnormalities [9]. Likewise, other comorbid conditions, including heart failure, morbid obesity, sleep apnoea, PA aneurysms and pulmonary embolism can affect the PA:A [30].

The study has many strengths, including the large cohort size, the prospective design and the generalisability achieved by including a large population of both healthy and sick individuals in the outpatient clinic setting. This is the first study to examine the PA:A ratio in a general population, rather than a carefully selected cohort such as those undergoing lung transplant evaluation or critically ill patients. However, it does also have several important limitations. First, PH was defined using echocardiographic measurements of PA systolic pressure, which have been shown to lack diagnostic accuracy in patients with hyperinflation and advanced obstructive lung disease [10]. The use of measurements from RHC might have revealed a greater number of patients with elevated pulmonary artery pressures, especially those with mild to moderate COPD. Second, the COPD group only comprised 10% of the study cohort and among this group, only 10.6% (n=22) had severe airflow obstruction. Increases in the risk of mortality were only observed in this small subset of the study cohort. These findings are consistent with those reported by Shin et al. [15] and suggest that the PA:A might have the greatest prognostic utility for mortality in severe COPD. Third, the study did not report acute exacerbations of COPD in the cohort. Exacerbations are an important confounder to consider, given the associations between these events and the PA:A with mortality. Future studies should evaluate effect modifications due to exacerbations and the resulting associations between the PA:A and mortality. Finally, although this cohort is representative of the larger population, one cannot help but notice the relative absence of other comorbid conditions that are associated with PH.

Overall, the study by Terzikhan et al. [26] demonstrates the utility of the PA:A in a cohort of patients with COPD, sampled from a general population. However, it also raises additional questions about our understanding of the PA:A. Would the prevalence of PA enlargement increase if a greater number of patients with conditions associated with PH were included in the cohort? How do exacerbations influence the associations between PA:A and mortality? Does the PA:A change over time, and if so, do changes influence the risk of mortality? This study reveals just how much we still have to learn about the utility of the PA:A ratio in COPD. Given the enormous public health burden that COPD presents, there is a need to better understand the implications of imaging-based biomarkers like the PA:A for future studies and for clinical practice. This study is an important first step in this process.

Disclosures

Supplementary Material

J.M. Wells ERJ-00750-2017_Wells

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received April 10, 2017.
  • Accepted April 17, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Chaouat A,
    2. Naeije R,
    3. Weitzenblum E
    . Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371–1385.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Minai OA,
    2. Chaouat A,
    3. Adnot S
    . Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010; 137: Suppl. 6, 39S–51S.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Seeger W,
    2. Adir Y,
    3. Barberà JA, et al.
    Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109–D116.
    OpenUrlFREE Full Text
  4. ↵
    1. Blanco I,
    2. Santos S,
    3. Gea J, et al.
    Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42: 982–992.
    OpenUrlAbstract/FREE Full Text
    1. Rietema H,
    2. Holverda S,
    3. Bogaard HJ, et al.
    Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31: 759–764.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Stolz D,
    2. Rasch H,
    3. Linka A, et al.
    A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619–628.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Taichman DB,
    2. Shin J,
    3. Hud L, et al.
    Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sun XG,
    2. Hansen JE,
    3. Oudiz RJ, et al.
    Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429–435.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Wells JM,
    2. Dransfield MT
    . Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis 2013; 8: 509–521.
    OpenUrl
  9. ↵
    1. Arcasoy SM,
    2. Christie JD,
    3. Ferrari VA, et al.
    Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735–740.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Fisher MR,
    2. Criner GJ,
    3. Fishman AP, et al.
    Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30: 914–921.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kovacs G,
    2. Reiter G,
    3. Reiter U, et al.
    The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration 2008; 76: 458–470.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Podolanczuk AJ,
    2. Oelsner EC,
    3. Barr RG, et al.
    High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J 2016; 48: 1442–1452.
    OpenUrlAbstract/FREE Full Text
    1. Oelsner EC,
    2. Lima JA,
    3. Kawut SM, et al.
    Noninvasive tests for the diagnostic evaluation of dyspnea among outpatients: the Multi-Ethnic Study of Atherosclerosis lung study. Am J Med 2015; 128: 171–180 e175.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Shin S,
    2. King CS,
    3. Brown AW, et al.
    Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Respir Med 2014; 108: 1626–1632.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Iyer AS,
    2. Wells JM,
    3. Vishin S, et al.
    CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 2014; 145: 824–832.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wells JM,
    2. Washko GR,
    3. Han MK, et al.
    Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367: 913–921.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Wells JM,
    2. Morrison JB,
    3. Bhatt SP, et al.
    Pulmonary artery enlargement is associated with cardiac injury during severe exacerbations of COPD. Chest 2016; 149: 1197–1204.
    OpenUrl
  17. ↵
    1. Truong QA,
    2. Massaro JM,
    3. Rogers IS, et al.
    Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham Heart Study. Circ Cardiovasc Imaging 2012; 5: 147–154.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Shin S,
    2. King CS,
    3. Puri N, et al.
    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47: 1445–1451.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Wells JM,
    2. Farris RF,
    3. Gosdin TA, et al.
    Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study. Lancet Respir Med 2016; 4: 636–645.
    OpenUrl
  20. ↵
    1. Huitema MP,
    2. Spee M,
    3. Vorselaars VM, et al.
    Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur Respir J 2016; 47: 673–676.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Nakanishi R,
    2. Rana JS,
    3. Shalev A, et al.
    Mortality risk as a function of the ratio of pulmonary trunk to ascending aorta diameter in patients with suspected coronary artery disease. Am J Cardiol 2013; 111: 1259–1263.
    OpenUrl
    1. Baptista R,
    2. Santiago I,
    3. Jorge E, et al.
    One-shot diagnostic and prognostic assessment in intermediate- to high-risk acute pulmonary embolism: the role of multidetector computed tomography. Rev Port Cardiol 2013; 32: 7–13.
    OpenUrlPubMed
  22. ↵
    1. Karakus G,
    2. Kammerlander AA,
    3. Aschauer S, et al.
    Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson 2015; 17: 79.
    OpenUrl
  23. ↵
    1. Terzikhan N,
    2. Bos D,
    3. Lahousse L, et al.
    Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. Eur Respir J 2017; 49: 1602168.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology, European Respiratory Society, International Society of Heart and Lung Transplantation, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
    OpenUrlFREE Full Text
  25. ↵
    1. Evans AM,
    2. Hardie DG,
    3. Peers C, et al.
    Hypoxic pulmonary vasoconstriction: mechanisms of oxygen-sensing. Curr Opin Anaesthesiol 2011; 24: 13–20.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Dournes G,
    2. Laurent F,
    3. Coste F, et al.
    Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease. Correlation with pulmonary hypertension. Am J Respir Crit Care Med 2015; 191: 63–70.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Dobrowolski P,
    2. Florczak E,
    3. Klisiewicz A, et al.
    Pulmonary artery dilation indicates severe obstructive sleep apnea in patients with resistant hypertension: the Resist-POL Study. Pol Arch Med Wewn 2016; 126: 222–229.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 6 Table of Contents
European Respiratory Journal: 49 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality
Aline N. Zouk, J. Michael Wells
European Respiratory Journal Jun 2017, 49 (6) 1700750; DOI: 10.1183/13993003.00750-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality
Aline N. Zouk, J. Michael Wells
European Respiratory Journal Jun 2017, 49 (6) 1700750; DOI: 10.1183/13993003.00750-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Epidemiology, occupational and environmental lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • CFTR: a missing link between smoking and chronic airway diseases?
  • Update March 2022: ERS guidelines for management of hospitalised COVID-19 patients
  • Improving IGRA interpretation: are IP-10 and MIG the solution?
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society